Skip to main content
. 2016 Apr 4;113(16):4470–4475. doi: 10.1073/pnas.1525349113

Fig. 3.

Fig. 3.

Dual cediranib+MEDI3617 therapy promotes edema control in Gl261 tumors. Gl261-bearing mice (n = 5–7) were treated with control (green bars), cediranib (red bars), or dual therapy (blue bars). Water content (edema) was measured on day 10 after treatment start by wet/dry weight ratio in the contralateral hemisphere (Contra) (A), ipsilateral hemisphere (Ipsi) (B), and tumor (C). Cediranib monotherapy significantly decreased water content in both the contralateral (P = 0.029) and ipsilateral (P = 0.024) hemispheres. Dual therapy also decreased water content compared with control-treated tumors, although the decrease did not reach statistical significance (contralateral P = 0.095; ipsilateral P = 0.052). There was no significant difference in edema in any of the tissues treated with dual therapy as compared with cediranib treatment. cedi, cediranib; cedi+M3617, cediranib+MEDI3617; Cont, control. Error bars represent the SEM. *P < 0.05 compared with control unless otherwise indicated.